{"id":391018,"date":"2016-11-09T00:00:00","date_gmt":"2016-11-09T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biolatr001-biopharma-biosimilars-emerging-biosimilars-oncology-zarxio-wave-3-us-2016\/"},"modified":"2026-05-13T11:41:23","modified_gmt":"2026-05-13T11:41:23","slug":"biolatr001-biopharma-biosimilars-emerging-biosimilars-oncology-zarxio-wave-3-us-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biolatr001-biopharma-biosimilars-emerging-biosimilars-oncology-zarxio-wave-3-us-2016\/","title":{"rendered":"Biosimilars | Emerging Biosimilars | Oncology | Zarxio Wave 3 | US | 2016"},"content":{"rendered":"<p>Biosimilars | Emerging Biosimilars | Oncology: Zarxio Launch Tracking (US) Wave 3 is the third and final installment in a series of syndicated reports designed to track physician perception and uptake of Sandoz\u2019s Zarxio (filgrastim-sndz), a biosimilar of Amgen\u2019s Neupogen and the first biosimilar to launch in the United States. Medical oncologists and hematology-oncologists in the United States were surveyed to assess their awareness and perception of Zarxio, uptake of the biosimilar over time, Zarxio&#8217;s effect on other G-CSFs, and promotional activity related to Zarxio and its competitors. Formulary coverage and restrictions associated with Zarxio and other G-CSFs were also evaluated.<\/p>\n","protected":false},"template":"","class_list":["post-391018","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-product-biosimilars","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391018\/revisions"}],"predecessor-version":[{"id":394141,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391018\/revisions\/394141"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}